David Epstein, the former CEO of Seagen Inc., has recently launched a new biotech company called Ottimo Pharma. Ottimo Pharma is focused on developing a unique cancer treatment that aims to address two distinct vulnerabilities in tumors through a dual-target approach.
The company's lead drug targets a specific protein that is also affected by Merck & Co.'s successful cancer therapy, Keytruda. Ottimo Pharma's innovative strategy positions them to potentially make significant advancements in cancer treatment, benefiting from Epstein's extensive experience in the biotech industry following Seagen's acquisition by Pfizer for $43 billion last year.